IP Library › Granted Patent US 12,599,565
Granted Patent B2
US 12,599,565 · App. 17/501,237 · Granted Apr 14, 2026

Stable benzimidazole formulation

Inventors: Adel Penhasi (Holon, IL); Avi Avramoff (Haifa, IL); Maxim Gomberg (Jerusalem, IL); Valerie Azoulay (Pardes Hana, IL)
Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
A61K9/2095A61K9/282A61K9/2866A61K31/4439A61K9/1676A61K9/5042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,565
App. No.
17/501,237
Granted
Apr 14, 2026
Kind
B2
Abstract

An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.

Claims (23)

1 . An omeprazole delayed release tablet consisting of:

a core consisting of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate; and an enteric coating over the core consisting of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, a coloring agent and less than 500 ppm of residual ammonium hydroxide;

wherein said monoethanol amine is prepared from an aqueous solution and is present in the coating in an amount of 1.195 weight %, 1.251 weight %, 1.28 weight %, 1.282 weight %, 1.325 weight %, 1.35 weight %, 1.360 weight %, 1.368 weight %, 1.388 weight %, 1.396 weight %, 1.44 weight %, 1.477 weight %, 1.59 weight %, or 1.75 weight % to reduce residual ammonium hydroxide in said tablet to a lower amount for toxicity/safety reasons.

2 . An omeprazole delayed release tablet consisting of:

a core and an enteric coating over the core,

wherein the core consists of about: 20 mg omeprazole, 203 mg lactose monohydrate, 10 mg sodium starch glycolate, 10 mg sodium stearate, and 7 mg sodium stearyl fumarate,

wherein the enteric coating consists of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, a coloring agent and less than 500 ppm of residual ammonium hydroxide;

wherein said monoethanol amine is prepared from an aqueous solution and is present in the coating in an amount of 1.195 weight %, 1.251 weight %, 1.28 weight %, 1.282 weight %, 1.325 weight %, 1.35 weight %, 1.360 weight %, 1.368 weight %, 1.388 weight %, 1.396 weight %, 1.44 weight %, 1.477 weight %, 1.59 weight %, or 1.75 weight % to reduce residual ammonium hydroxide in said tablet to a lower amount for toxicity/safety reasons.

3 . An omeprazole delayed release tablet consisting of:

a core and an enteric coating over the core,

wherein the core consists of about: 8 weight % omeprazole, 81.2 weight % lactose monohydrate, 4 weight % sodium starch glycolate, 4 weight % sodium stearate, and 2.8 weight % sodium stearyl fumarate by weight percent of the core,

wherein the enteric coating consists of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, a coloring agent and less than 500 ppm of residual ammonium hydroxide by weight percent of the enteric coating;

wherein said monoethanol amine is prepared from an aqueous solution and is present in the coating in an amount of 1.195 weight %, 1.251 weight %, 1.28 weight %, 1.282 weight %, 1.325 weight %, 1.35 weight %, 1.360 weight %, 1.368 weight %, 1.388 weight %, 1.396 weight %, 1.44 weight %, 1.477 weight %, 1.59 weight %, or 1.75 weight % to reduce residual ammonium hydroxide in said tablet to a lower amount for toxicity/safety reasons.

4 . The omeprazole delayed release tablet of claim 1 , wherein the omeprazole is present in the core in an amount of 20 mg.

5 . The omeprazole delayed release tablet of claim 1 , wherein the omeprazole is present in the core in an amount of about 8 weight %.

6 . The omeprazole delayed release tablet of claim 2 , wherein the HPMC acetate succinate is present in the coating in an amount of 32 mg, the triethyl citrate is present in the coating in an amount of 4.5 mg, the sodium lauryl sulfate is present in the coating in an amount of 0.5 mg, the talc is present in the coating in an amount of 8.14 mg, and the coloring agent is present in the coating in an amount of 10.8 mg.

7 . The omeprazole delayed release tablet of claim 3 , wherein the HPMC acetate succinate is present in an amount of 56.14 weight % of the coating, the triethyl citrate is present in an amount of 7.89 weight % of the coating, the sodium lauryl sulfate is present in an amount of 0.88 weight % of the coating, the talc is present in an amount of 14.28 weight % of the coating, and the coloring agent is present in an amount of 18.95 weight % of the coating.

8 . The omeprazole delayed release tablet of claim 1 , wherein the monoethanol amine is present in the coating in an amount of 1.195 weight %.

9 . The omeprazole delayed release tablet of claim 1 , wherein the monoethanol amine is present in the coating in an amount of 1.75 weight %.

10 . The omeprazole delayed release tablet of claim 2 , wherein the monoethanol amine is present in the coating in an amount of 1.195 weight %.

11 . The omeprazole delayed release tablet of claim 2 , wherein the monoethanol amine is present in the coating in an amount of 1.75 weight %.

12 . The omeprazole delayed release tablet of claim 3 , wherein the monoethanol amine is present in the coating in an amount of 1.195 weight %.

13 . The omeprazole delayed release tablet of claim 3 , wherein the monoethanol amine is present in the coating in an amount of 1.75 weight %.

Assignments (1)
CHANGE OF ADDRESS Recorded May 18, 2022
From: DEXCEL PHARMA TECHNOLOGIES LTD.
To: DEXCEL PHARMA TECHNOLOGIES LTD.
Reel/Frame 060103/0875 →
Continuity (4)
Continuation 14053611 · Oct 15, 2013
Continuation 12866255
Provisional Application 61071557 · May 6, 2008
Related Publication 20220031622A1 · Feb 3, 2022
References Cited (142)
US 3634271A · Friedman · 1972 [cited by applicant]
US 4017647A · Ohno et al. · 1977 [cited by applicant]
US 4786505A · Lovgren et al. · 1988 [cited by applicant]
US 4853230A · Lovgren et al. · 1989 [cited by applicant]
US 4888367A · Quigley et al. · 1989 [cited by applicant]
US 5045321A · Makino et al. · 1991 [cited by applicant]
US 5093132A · Makino et al. · 1992 [cited by applicant]
US 5225202A · Hodges et al. · 1993 [cited by applicant]
US 5232706A · Palomo Coll · 1993 [cited by applicant]
US 5330982A · Tyers · 1994 [cited by applicant]
US 5376385A · Barton et al. · 1994 [cited by applicant]
US 5433959A · Makino et al. · 1995 [cited by applicant]
US 5508276A · Anderson · 1996 [cited by applicant]
US 5536735A · Takechi et al. · 1996 [cited by applicant]
US 5639478A · Makino · 1997 [cited by applicant]
US 5690960A · Bengtsson · 1997 [cited by examiner]
US 5753265A · Bergstrand · 1998 [cited by applicant]
US 5817338A · Bergstrand · 1998 [cited by applicant]
US 5879708A · Makino et al. · 1999 [cited by applicant]
US 6013281A · Lundberg · 2000 [cited by applicant]
US 6017560A · Makino et al. · 2000 [cited by applicant]
US 6077541A · Chen et al. · 2000 [cited by applicant]
US 6096340A · Chen et al. · 2000 [cited by applicant]
US 6123962A · Makino et al. · 2000 [cited by applicant]
US 6149942A · Scheiwe · 2000 [cited by applicant]
US 6174548B1 · Chen et al. · 2001 [cited by applicant]
US 6228400B1 · Lee et al. · 2001 [cited by applicant]
US 6245351B1 · Nara et al. · 2001 [cited by applicant]
US 6262085B1 · Whittle · 2001 [cited by applicant]
US 6268385B1 · Whittle · 2001 [cited by applicant]
US 6296875B1 · Makino et al. · 2001 [cited by applicant]
US 6326384B1 · Whittle · 2001 [cited by applicant]
US 6380234B1 · Makino · 2002 [cited by applicant]
US 6521256B2 · Makino · 2003 [cited by applicant]
US 6602522B1 · Chen · 2003 [cited by applicant]
US 6623752B1 · Fischer et al. · 2003 [cited by applicant]
US 6623759B2 · Heese · 2003 [cited by applicant]
US 6699885B2 · Phillips · 2004 [cited by applicant]
US 6726927B2 · Chen · 2004 [cited by applicant]
US 6733778B1 · Chen · 2004 [cited by applicant]
US 6749864B2 · Makino · 2004 [cited by applicant]
US 6780435B2 · Chen · 2004 [cited by applicant]
US 6855336B2 · Chen · 2005 [cited by applicant]
US 7988999B2 · Dietrich et al. · 2011 [cited by applicant]
US 9023391B2 · Lahav et al. · 2015 [cited by applicant]
US 20020039597A1 · Ukai · 2002 [cited by applicant]
US 20020054913A1 · Heese · 2002 [cited by applicant]
US 20020098242A1 · Darder · 2002 [cited by applicant]
US 20020128293A1 · Knopfler · 2002 [cited by applicant]
US 20020160046A1 · Robinson · 2002 [cited by applicant]
US 20030021844A1 · Barthelemy et al. · 2003 [cited by applicant]
US 20030064107A1 · Yu · 2003 [cited by examiner]
US 20030091643A1 · Friesen · 2003 [cited by applicant]
US 20030175348A1 · Kofler · 2003 [cited by applicant]
US 20030228363A1 · Patel · 2003 [cited by examiner]
US 20030236285A1 · Patel · 2003 [cited by applicant]
US 20040028737A1 · Ceshpande · 2004 [cited by applicant]
US 20040175427A1 · Chen · 2004 [cited by applicant]
US 20040209919A1 · Makino · 2004 [cited by applicant]
US 20040213847A1 · Matharu · 2004 [cited by applicant]
US 20050163846A1 · Aoki · 2005 [cited by applicant]
US 20060003005A1 · Cao · 2006 [cited by examiner]
US 20060093680A1 · Humar · 2006 [cited by examiner]
US 20060159762A1 · Stanic Ljubin et al. · 2006 [cited by applicant]
US 20060165778A1 · Hassan · 2006 [cited by applicant]
US 20060204577A1 · Crew et al. · 2006 [cited by applicant]
US 20070065513A1 · Avramoff · 2007 [cited by examiner]
US 20070196485A1 · Lahav · 2007 [cited by examiner]
US 20070243250A1 · Heinicke · 2007 [cited by examiner]
US 20080131467A1 · Nelson · 2008 [cited by examiner]
US 20080161364A1 · Tatsumi et al. · 2008 [cited by applicant]
US 20090175935A1 · Setty · 2009 [cited by examiner]
US 20090297441A1 · Canham et al. · 2009 [cited by applicant]
US 20100183710A1 · Bolugoddu · 2010 [cited by applicant]
US 20100297226A1 · Penhasi · 2010 [cited by examiner]
DE 19626045 · 1998 [cited by applicant]
EP 0005129B1 · 1981 [cited by applicant]
EP 0124495B1 · 1987 [cited by applicant]
EP 237200B1 · 1992 [cited by applicant]
EP 519144B1 · 1997 [cited by applicant]
FR 2692146A1 · 1992 [cited by applicant]
GB 2189698A · 1987 [cited by applicant]
WO WO8300435A1 · 1983 [cited by applicant]
WO WO9624338 · 1996 [cited by applicant]
WO WO9637195 · 1996 [cited by applicant]
WO WO9712581 · 1997 [cited by applicant]
WO WO9800114 · 1998 [cited by applicant]
WO WO9840069 · 1998 [cited by applicant]
WO WO9850019 · 1998 [cited by applicant]
WO WO9925323 · 1999 [cited by applicant]
WO WO9927917 · 1999 [cited by applicant]
WO WO0012064 · 2000 [cited by applicant]
WO WO0050038 · 2000 [cited by applicant]
WO WO0078284A1 · 2000 [cited by applicant]
WO WO0124777 · 2001 [cited by applicant]
WO WO0211699 · 2002 [cited by applicant]
WO WO0219991 · 2002 [cited by applicant]
WO WO02102356 · 2002 [cited by applicant]
WO WO03024449 · 2003 [cited by applicant]
WO WO03072087 · 2003 [cited by applicant]
WO WO03077888 · 2003 [cited by applicant]
WO WO03103638 · 2003 [cited by applicant]
WO WO04000279A1 · 2003 [cited by applicant]
WO WO04014345 · 2004 [cited by applicant]
WO WO04050058 · 2004 [cited by applicant]
WO WO04050068 · 2004 [cited by applicant]
WO WO04089333 · 2004 [cited by applicant]
What is pH and how is it measured? (2003). [cited by examiner]
Important Biological Buffers. [cited by examiner]
Gilbar “A Guide to Enteral Drug Administration in Palliative Care”. Mar. 1999. [cited by examiner]
PH Adjusting Database Jun. 2007. [cited by examiner]
Ansel, Howard C., et al., “ [cited by applicant]
Ansel, Howard C., et al., “ [cited by applicant]
Dexcel Responses to DRL Invalidity Contentions (redacted) dated May 9, 2016, (236p). [cited by applicant]
Dexcel Responses to SUN's Invalidity Contentions (redacted) dated May 20, 2016, (138p). [cited by applicant]
DRL Invalidity Contentions (redacted) dated Mar. 17, 2016 (65p). [cited by applicant]
SUN Invalidity Contentions (redacted) dated Apr. 5, 2016 (42p). [cited by applicant]
Bloor, J.R., et al., “ [cited by applicant]
Borukhov, Itmar et al., “Polyelectrolyte Titration: Theory and Experiment,” May 2000, https://arxiv.org/pdf/cond-mat/0005306.pdf. (13p). [cited by applicant]
Clinical Pharmacology and Biopharmaceutics Review New Drug Application, Center For Drug Evaluation and Research, OCPB Review, Cymbalta® (Duloxetine HCl) EC-Capsules; C:/dmautop/temp/21427 Review Final.doc, last printed … [cited by applicant]
Eudragit® L30D-55, Specification and Test Methods, Evonik Industries AG, May 2014 (8p). [cited by applicant]
Handbook of Granulation Technology, http://www.gmpua.com/Process/Tablet/Granulation/Granulation Technology, Taylor & Francis Group, LLC (2005), 624 pages. [cited by applicant]
Heinamaki, J.T., et al., “ [cited by applicant]
Hilton, A.K. et al., “ [cited by applicant]
Important Biological Buffers, Google date Oct. 25, 2007, http://staff.ustc.edu.cn/liuyz/methods/buffer.htm, Aug. 31, 2015. (2p). [cited by applicant]
Kohlmann, Frederick J., “ [cited by applicant]
Lin, Feng-Chih, et al., “ [cited by applicant]
Palaniswamy, R., et al., “Association Behavior of Poly(methacrylic acid)-block-Poly(methylmethacrylate) in Aqueous Medium: Potentiometric and Laser Light Scattering Studies,” (8p). [cited by applicant]
Pilbrant, A., et al., “ [cited by applicant]
Rudnic, Edward et al., “ [cited by applicant]
Stafford, J.W., et al., “ [cited by applicant]
Subburayalu, Raja et al., “ [cited by applicant]
“Talc” retrieved from internet (rruff.geo.arizona.edu/doclib/hom/talc.pdf) on Jul. 27, 2006. [cited by applicant]
International Search Report to PCT Application No. PCT/IL00/00364, dated Oct. 24, 2000 (1 p). [cited by applicant]
International Preliminary Examination Report to PCT Application No. PCT/IL00/00364, dated Sep. 17, 2001 (4p). [cited by applicant]
Search Report to European Application EP1187599 dated Apr. 30, 2004. [cited by applicant]
Office Action to European Application EP20090742569 dated Aug. 18, 2011. [cited by applicant]
Office Action to European Application EP1187599 dated Mar. 22, 2005. [cited by applicant]
Office Action to European Application EP1187599 dated Aug. 8, 2006. [cited by applicant]
Office Action to European Application EP1187599 dated Apr. 23, 2007. [cited by applicant]
Office Action to Israel Application IL208925 dated Dec. 19, 2012. [cited by applicant]
Important Biological Buffers. Oct. 25, 2007. [cited by applicant]